Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | RRM2 | P31350 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5710515 | 0.98 | KDM1A (0.49) | KDM1ATRPV1MAP3K11APPKCNH2 | |
| SCHEMBL29636503 | 0.84 | KDM1A (0.60) | KDM1ATRPV1MAP3K11APPKCNH2 | |
| SCHEMBL14234051 | 0.84 | KDM1A (0.60) | KDM1ATRPV1MAP3K11APPKCNH2 | |
| SCHEMBL12789566 | 0.81 | KDM1A (0.49) | KDM1ATRPV1MAP3K11APPKCNH2 | |
| SCHEMBL27833127 | 0.78 | GBA1 (0.56) | TRPV1RRM2 | |
| SCHEMBL13002821 | 0.77 | ALDH1A1 (0.38) | KDM1ATRPV1PIK3CAMTORRRM2 | |
| SCHEMBL14234048 | 0.76 | KDM1A (0.53) | KDM1AAPPEGFR | |
| Hydrochloric Acid SCHEMBL5710510 | 0.76 | KDM1A (0.45) | KDM1ATRPV1MAP3K11APPKCNH2 | |
| SCHEMBL14234303 | 0.76 | KDM1A (0.65) | KDM1A | |
| SCHEMBL29636433 | 0.76 | KDM1A (0.53) | KDM1AAPPEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3738961-B1 | HETEROCYCLIC COMPOUND AS CSF-1R INHIBITOR AND USE THEREOF | MEDSHINE DISCOVERY INC (CN) | 2022-08-31 | — | — | EP | disclosed |
| US-11384065-B2 | Heterocyclic compound as CSF-1R inhibitor and use thereof | MEDSHINE DISCOVERY INC. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20210107894-A1 | HETEROCYCLIC COMPOUND AS CSF-1R INHIBITOR AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2021-04-15 | — | — | US | disclosed |
| WO-2020261294-A1 | NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | MANKIND PHARMA LTD. (IN) | 2020-12-30 | — | — | WO | disclosed |
| EP-3738961-A1 | HETEROCYCLIC COMPOUND AS CSF-1R INHIBITOR AND USE THEREOF | Medshine Discovery Inc. (CN) | 2020-11-18 | — | — | EP | disclosed |
| WO-2018011376-A1 | PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2018-01-18 | — | — | WO | disclosed |
| CN-101538246-B | Pyrimidine amide compounds as PGDS inhibitors | AVENTIS PHARMA INC | 2014-07-16 | — | — | CN | disclosed |
| CN-101538246-A | Pyrimidine amide compounds as pgds inhibitors | AVENTIS PHARMA INC | 2009-09-23 | — | — | CN | disclosed |
| CN-101282943-A | Pyrimidine amide compounds as PGDS inhibitors | AVENTIS PHARMA INC (US) | 2008-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384065-B2 | Heterocyclic compound as CSF-1R inhibitor and use thereof | CSF1R, CSF3R, IL1RN | KDM1A 2477/4885TRPV1 2529/4885MAP3K11 996/4885 |
| US-20210107894-A1 | HETEROCYCLIC COMPOUND AS CSF-1R INHIBITOR AND USE THEREOF | CSF1R, CSF3R, IL1RN | KDM1A 2477/4885TRPV1 2529/4885MAP3K11 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.